A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
NeoComplete Paraneoplastic Evaluation with Recombx : 91636
MessageSerum must be separated from whole blood within 48 hours of collection.
Test Code
PARANE or 91636
Alias/See Also
PCA1, ANNA-1, Ma2, PNM1, Ma1, CRMP5, ANNA2, PNM2, AMPHS
CPT Codes
86255x3, 86341, 83519x2, 86596, 83520x8
Includes
Recombx Amphiphysin Autoantibody Test, CASPR2 Antibody Test, GAD65 Neurological Syndrome Antibody Test, Ganglionic AChR Antibody Test, LEMS (VGCC) Antibody Test, LGI1 Autoantibody Test, NMDA Receptor (NR1-subunit) Autoantibody Test, Recombx CAR (Anti-Recoverin) Autoantibody Test, Recombx CV2 Antibody Test, Recombx MaTa Autoantibody Test, Recombx Ri Autoantibody Test, Recombx Yo Autoantibody Test, Recombx Zic4 Antibody Test, Recombx Hu Autoantibody Test, VGKC Antibody Test
Instructions
Serum separator tube.
Transport Container
Centrifuge serum separator tube within 48 hours of collection and transport, 2 mL serum (Min: 0.5 mL).
Transport Temperature
Refrigerated.
Specimen Stability
Room temperature: 72 hours; Refrigerated: 21 days; Frozen: 28 days
Methodology
Automated Nanoliter Scale Immunoassay; Enzyme Linked Immunosorbent Immunoassay (ELISA); Radioimmunoassay (RIA); Immunofluorescence Assay (IFA)
Setup Schedule
Monday & Wednesday
Report Available
7-10 days (From receipt at performing laboratory)
Limitations
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Reference Range
See Laboratory Report
Clinical Significance
Anti-Hu, anti-CV2, anti-Yo, anti-Ri, anti-CAR, anti-Ma, anti-Ta, anti-Zic4 antibodies, anti-voltage gated calcium channels (VGCC), anti-P/Q type and voltage gated potassium channels (VGKC), anti- Ganglionic AChR, anti-Amphiphysin, anti-NMDA receptor (NR1-subunit), anti-LGI1, anti-CASPR2, and anti-GAD65 are found in patients with the acute or subacute onset of limbic encephalitis, brainstem encephalitis, focal cortical encephalitis, myelitis, cerebellar degeneration, opsoclonus/myoclonus, retinopathy, sensory neuropathy, autonomic dysfunction, Stiff Person Syndrome and/or Lambert-Eaton Myasthenic Syndrome. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.
Performing Laboratory
Quest Diagnostics